JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

7.17 -0.69

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.97

Max

7.25

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

118.571

84.243

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+60.03% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 26. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-557M

1.3B

Iepriekšējā atvēršanas cena

7.86

Iepriekšējā slēgšanas cena

7.17

Ziņu noskaņojums

By Acuity

50%

50%

144 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. febr. 17:25 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

2026. g. 9. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

2026. g. 9. febr. 23:43 UTC

Tirgus saruna

Gold Falls on Possible Technical Correction -- Market Talk

2026. g. 9. febr. 23:14 UTC

Tirgus saruna

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

2026. g. 9. febr. 22:29 UTC

Tirgus saruna

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

2026. g. 9. febr. 22:19 UTC

Tirgus saruna

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

2026. g. 9. febr. 22:08 UTC

Tirgus saruna

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

2026. g. 9. febr. 22:01 UTC

Peļņas

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

2026. g. 9. febr. 21:59 UTC

Peļņas

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

2026. g. 9. febr. 21:59 UTC

Peļņas

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

2026. g. 9. febr. 21:58 UTC

Peļņas

Friedman Industries 3Q Sales $168M >FRD

2026. g. 9. febr. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 9. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. febr. 21:48 UTC

Peļņas

Friedman Industries 3Q EPS 43c >FRD

2026. g. 9. febr. 21:17 UTC

Peļņas

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

2026. g. 9. febr. 21:13 UTC

Tirgus saruna

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

2026. g. 9. febr. 21:04 UTC

Peļņas

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

2026. g. 9. febr. 20:30 UTC

Tirgus saruna

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

2026. g. 9. febr. 20:02 UTC

Tirgus saruna

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

2026. g. 9. febr. 19:42 UTC

Tirgus saruna

Japan's Yield Curve Expected to Flatten -- Market Talk

2026. g. 9. febr. 19:31 UTC

Tirgus saruna

Nike Seen Regaining Relevance With Consumers -- Market Talk

2026. g. 9. febr. 19:27 UTC

Tirgus saruna

Gold Climbs Back Over $5,000/oz -- Market Talk

2026. g. 9. febr. 19:05 UTC

Tirgus saruna

Nike Returns to List of Hottest Brands -- Market Talk

2026. g. 9. febr. 18:19 UTC

Tirgus saruna

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

2026. g. 9. febr. 17:41 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

2026. g. 9. febr. 17:31 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

2026. g. 9. febr. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 9. febr. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. febr. 17:17 UTC

Tirgus saruna

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

2026. g. 9. febr. 17:16 UTC

Peļņas

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

60.03% augšup

Prognoze 12 mēnešiem

Vidējais 11.57 USD  60.03%

Augstākais 13 USD

Zemākais 9 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

6

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

144 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat